ArteriosclerosisPhase 3NCT06008756
Enlicitide Decanoate (MK-0616 Oral PCSK9 Inhibitor) Cardiovascular Outcomes Study (MK-0616-015) CORALreef Outcomes
A Phase 3 study testing Enlicitide Decanoate in people with Arteriosclerosis and Hypercholesterolaemia, run by Merck Sharp & Dohme LLC at 669 sites in 29 countries.
Trial summary
This is a phase 3, randomized, placebo-controlled study of the efficacy and safety of enlicitide decanoate, an oral proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitor, in participants with high cardiovascular risk. Read more about this study
- Who is it for?
- Ages 18 years and older
- Conditions the study is for
- Arteriosclerosis, Hypercholesterolaemia
- What is being tested?
- Enlicitide Decanoate
- Type of treatment
- Pill or oral medicine
- Could I receive a placebo?
- Yes, some participants may receive a placebo
- How many people
- 14,550 participants
- Where
- 669 sitesin 29 countries
- Study dates
- 9 Oct 2023to 29 Nov 2031
- Phase
- Phase 3
- Are there results?
- Not yet: the study is under way
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 18 years and older
- All sexes
- No healthy volunteers
- Adult, Older adult
Who may be able to join
- Meets one of the following:
- Age ≥18 years with a history of a major atherosclerotic cardiovascular disease (ASCVD) event defined as at least 1 of the following: ≥30 days post MI (presumed Type 1 due to plaque rupture or erosion); ≥30 days post ischemic stroke (presumed due to atherosclerosis); or ≥30 days post successful peripheral (carotid or lower extremity) arterial revascularization (surgical or endovascular) or major (ankle or above) amputation due to atherosclerosis; or
- High risk for first major ASCVD event defined as at least 1 of the following: Age ≥50 years with evidence of coronary artery disease; Age ≥50 years with evidence of atherosclerotic cerebrovascular disease; Age ≥50 years with evidence of peripheral arterial disease; or Age ≥60 years with diabetes mellitus and at least one of the following: microvascular disease or urine albumin-creatinine ratio ≥30 mg/mmol within 6 months before Visit 1, daily insulin use, or diabetes for ≥10 years
- Has fasted lipid values (evaluated by the Central Laboratory) at Visit 1 (Screening) as follows:
- History of major ASCVD Event: LDL-C ≥70 mg/dL (1.81 mmol/L) OR non-HDL-C ≥100 mg/dL (2.59 mmol/L)
- High risk for first major ASCVD Event: LDL-C ≥90 mg/dL (2.33 mmol/L) OR non-HDL-C ≥120 mg/dL (3.11 mmol/L)
- Is treated with moderate- or high-intensity statin (± nonstatin lipid-lowering therapy [LLT]) at Visit 1
- Is on a stable dose of all background LLTs (including statin and nonstatin agents) for at least 30 days before Visit 1 (Screening) with no medication or dose changes planned during the participation in the study
Who cannot join
- Has a history of homozygous familial hypercholesterolemia (FH) based on genetic or clinical criteria, compound heterozygous FH, or double heterozygous FH
- Has New York Heart Association Class IV heart failure, last known Left Ventricular Ejection Fraction ≤25% by any imaging method, or had a Heart Failure hospitalization within 3 months before Visit 1 (Screening)
- Has recurrent ventricular tachycardia within 3 months prior to randomization
- Has a planned arterial revascularization procedure
- Is undergoing or previously underwent an LDL-C apheresis program within 3 months before Visit 1 (Screening) or plans to initiate an LDL-C apheresis program
- Was previously treated/is being treated with certain other cholesterol lowering medications, including protein convertase subtilisin/kexin type 9 (PCSK9) inhibitors without adequate washout.
- Has a fasting triglyceride value ≥400 mg/dL (≥4.52 mmol/L) at Visit 1 (Screening)
Trial locations and contacts
669 sites in 29 countries.
669 sites in 29 countries
United States132 sites
New Mexico Clinical Research & Osteoporosis Center ( Site 0005)
Albuquerque, New Mexico, 87106
Advanced Cardiovascular - Alexander City ( Site 0156)
Alexander City, Alabama, 35010
PharmaTex Research, LLC ( Site 0182)
Amarillo, Texas, 79106
Velocity Clinical Research, Anderson ( Site 0022)
Anderson, South Carolina, 29621
University of Colorado Anschutz Medical Campus-University of Colorado Hospital Cardiac and Vascular ( Site 0146)
Aurora, Colorado, 80045
Texas Diabetes and Endocrinology, P.A. ( Site 0187)
Austin, Texas, 78731
Northeast Cardiology Associates ( Site 0168)
Bangor, Maine, 04401
National Heart Institute-Research ( Site 0077)
Beverly Hills, California, 90211
Velocity Clinical Research, Binghamton ( Site 0063)
Binghamton, New York, 13905
Central Research Associates ( Site 0118)
Birmingham, Alabama, 35205
St. Vincent's Birmingham Hospital ( Site 0181)
Birmingham, Alabama, 35205
Central Alabama Research ( Site 0109)
Birmingham, Alabama, 35209
Bingham Memorial Hospital ( Site 0195)
Blackfoot, Idaho, 83221
Excel Medical Clinical Trials ( Site 0052)
Boca Raton, Florida, 33434
Brigham and Women's Hospital-Cardiovascular Medicine ( Site 0147)
Boston, Massachusetts, 02115
Boston Clinical Trials ( Site 0029)
Boston, Massachusetts, 02131
Flourish Research - Bowie ( Site 0190)
Bowie, Maryland, 20715
Advanced Heart Care - Bridgewater Route 22 ( Site 0160)
Bridgewater, New Jersey, 08807
Holston Medical Group ( Site 0106)
Bristol, Tennessee, 37620
Burke Internal Medicine and Research ( Site 0035)
Burke, Virginia, 22015
Capital Area Research, LLC ( Site 0139)
Camp Hill, Pennsylvania, 17011
Charlottesville Medical Research ( Site 0030)
Charlottesville, Virginia, 22911
Synexus Clinical Research US, Inc. ( Site 0084)
Chicago, Illinois, 60602
Great Lakes Clinical Trials - Ravenswood ( Site 0056)
Chicago, Illinois, 60640
Velocity Clinical Research, Springdale ( Site 0112)
Cincinnati, Ohio, 45246
Cleveland Clinic Main ( Site 0121)
Cleveland, Ohio, 44195
Centennial Medical Group ( Site 0179)
Columbia, Maryland, 21045
The Ohio State Wexner Medical Center ( Site 0200)
Columbus, Ohio, 43203
Remington-Davis, Inc. ( Site 0183)
Columbus, Ohio, 43215
Avant Research Associates ( Site 0103)
Crowley, Louisiana, 70526
Advanced Pharma Research ( Site 0040)
Cutler Bay, Florida, 33189
Southwest Family Medicine Associates ( Site 0189)
Dallas, Texas, 75235
Alliance for Multispecialty Research, LLC ( Site 0076)
Daphne, Alabama, 36526
Premier Cardiovascular Institute ( Site 0136)
Dayton, Ohio, 45414
Alliance for Multispecialty Research, LLC. ( Site 0171)
Dearborn, Michigan, 48126
Duke University Health System (DUHS) ( Site 0153)
Durham, North Carolina, 27710
Skyline Medical Center/CCT Research ( Site 0148)
Elkhorn, Nebraska, 68022
Alliance for Multispecialty Research - Medisphere Medical Research Center ( Site 0080)
Evansville, Indiana, 47714
Virginia Heart ( Site 0097)
Falls Church, Virginia, 22042
Lillestol Research ( Site 0025)
Fargo, North Dakota, 58104
G&L Research ( Site 0042)
Foley, Alabama, 36535
Alliance for Multispecialty Research, LLC ( Site 0083)
Fort Myers, Florida, 33912
Parkview Research Center at Parkview Regional Medical Center ( Site 0154)
Fort Wayne, Indiana, 46845
NextStage Clinical Research - Phoenix - (01) ( Site 0191)
Glendale, Arizona, 85306
Altru Health System ( Site 0197)
Grand Forks, North Dakota, 58201
Healthy Heart Cardiology ( Site 0113)
Grand Rapids, Michigan, 49546
Velocity Clinical Research, Gulfport ( Site 0038)
Gulfport, Mississippi, 39503
Great Lakes Clinical Trials - Gurnee ( Site 0134)
Gurnee, Illinois, 60031
Healthcare Research Network - St. Louis ( Site 0053)
Hazelwood, Missouri, 63042
Prolato Clinical Research Center ( Site 0108)
Houston, Texas, 77054
Franciscan Physician Network - Indiana Heart Physicians ( Site 0141)
Indianapolis, Indiana, 46237
Westside Center for Clinical Research ( Site 0049)
Jacksonville, Florida, 32205
University of Florida - Jacksonville ( Site 0166)
Jacksonville, Florida, 32209
East Coast Institute for Research, LLC ( Site 0031)
Jacksonville, Florida, 32216
Jacksonville Center for Clinical Research ( Site 0048)
Jacksonville, Florida, 32216
University of Kansas Medical Center ( Site 0004)
Kansas City, Kansas, 66160
Alliance for Multispecialty Research, LLC ( Site 0071)
Kansas City, Missouri, 64114
Holston Medical Group ( Site 0047)
Kingsport, Tennessee, 37660
Alliance for Multispecialty Research, LLC ( Site 0008)
Knoxville, Tennessee, 37909
UCSD - Altman Clinical and Translational Research Institute (ACTRI) ( Site 0130)
La Jolla, California, 92037
East Coast Institute for Research ( Site 0034)
Lake City, Florida, 32055
Chemidox Clinical Trials ( Site 0145)
Lancaster, California, 93534
Excel Clinical Research, LLC ( Site 0123)
Las Vegas, Nevada, 89109
Clinical Research of South Nevada ( Site 0135)
Las Vegas, Nevada, 89121-4350
Alliance for Multispecialty Research, LLC ( Site 0027)
Lexington, Kentucky, 40509
Velocity Clinical Research at The Pioneer Heart Institute, Lincoln ( Site 0078)
Lincoln, Nebraska, 68510
CHI Health Clinic Heart Institute ( Site 0180)
Lincoln, Nebraska, 68526
Medical Investigations Inc. ( Site 0188)
Little Rock, Arkansas, 72211
South Denver Cardiology Associates ( Site 0167)
Littleton, Colorado, 80120
Velocity Clinical Research, Westlake ( Site 0039)
Los Angeles, California, 90057
L-MARC Research Center ( Site 0001)
Louisville, Kentucky, 40213
The Jones Center Clinical Research ( Site 0032)
Macon, Georgia, 31210
Carient Heart & Vascular - Manassas ( Site 0170)
Manassas, Virginia, 20109
Manassas Clinical Research Center ( Site 0007)
Manassas, Virginia, 20110
Central New York Clinical Research ( Site 0044)
Manlius, New York, 13104
Fairview Health Services ( Site 0024)
Maplewood, Minnesota, 55109
Columbus Clinical Services ( Site 0026)
Miami, Florida, 33125
Miami Cardiac & Vascular Institute-Ambulatory Research ( Site 0059)
Miami, Florida, 33173
Inpatient Research Clinic ( Site 0041)
Miami Lakes, Florida, 33014
Abbott Northwestern Hospital ( Site 0199)
Minneapolis, Minnesota, 55407
University of Minnesota, Lillehei Clinical Research Unit ( Site 0193)
Minneapolis, Minnesota, 55455
Eminat ( Site 0082)
Miramar, Florida, 33027
IMA Clinical Research- Monroe- North 18th Street ( Site 0111)
Monroe, Louisiana, 71201
North Shore Diabetes & Endocrine Associates ( Site 0165)
New Hyde Park, New York, 11042
Mid Hudson Medical Research ( Site 0087)
New Windsor, New York, 12553
NYU Langone Health ( Site 0099)
New York, New York, 10016
Health Research of Hampton Roads, Inc. ( Site 0043)
Newport News, Virginia, 23606
Alliance for Multispecialty Research, LLC ( Site 0068)
Norfolk, Virginia, 23502
Coastal Carolina Research Center ( Site 0006)
North Charleston, South Carolina, 29405
Ocala Research Institute - Ocala - Southwest 20th Place ( Site 0079)
Ocala, Florida, 34471
Permian Research Foundation ( Site 0157)
Odessa, Texas, 79761
South Oklahoma Heart Research ( Site 0164)
Oklahoma City, Oklahoma, 73135
Alliance for Multispecialty Research, LLC ( Site 0173)
Park Ridge, Illinois, 60068
Carbon Health - Pasadena ( Site 0149)
Pasadena, California, 91101
LinQ Research ( Site 0101)
Pearland, Texas, 77584
Synexus Clinical Research US, Inc.-Synexus Clinical Research US, Inc - Central Phoenix ( Site 0066)
Phoenix, Arizona, 85020
Progressive Medical Research ( Site 0045)
Port Orange, Florida, 32127
Monument Health Clinical Research, a department of Monument -Monument Health Clinical Research, a d ( Site 0009)
Rapid City, South Dakota, 57701
Reid Physician Associates ( Site 0174)
Richmond, Indiana, 47374
Rochester Clinical Research, Inc. ( Site 0098)
Rochester, New York, 14609
Laurelton Heart Specialist PC ( Site 0092)
Rosedale, New York, 11422
St Johns Center for Clinical Research ( Site 0016)
Saint Augustine, Florida, 32086
Synexus Clinical Research US, Inc. ( Site 0086)
Salt Lake City, Utah, 84106
Highland Clinical Research ( Site 0122)
Salt Lake City, Utah, 84124
Northeast Clinical Research of San Antonio ( Site 0011)
San Antonio, Texas, 78233
Discovery Clinical Trials ( Site 0096)
San Antonio, Texas, 78258
Carbon Health - San Mateo - Hillsdale Mall ( Site 0151)
San Mateo, California, 94403
Guthrie Medical Group, P.C. ( Site 0176)
Sayre, Pennsylvania, 18840
Cardiology Associates of Fairfield County, P.C. ( Site 0159)
Stamford, Connecticut, 06905
Centricity Research Suffolk Family Medicine ( Site 0105)
Suffolk, Virginia, 23435
Sugar Lakes Family Practice, PA ( Site 0094)
Sugar Land, Texas, 77479
America Clinical Trials-Research Dept ( Site 0104)
Tarzana, California, 91356-3551
Healthcare Research Network - Chicago ( Site 0051)
Tinley Park, Illinois, 60477
Premiere Medical Center ( Site 0093)
Toluca Lake, California, 91602
LinQ Research - Tomball ( Site 0208)
Tomball, Texas, 77375
Northwest Houston Heart Center-Northwest Houston Clinical Research, PLLC ( Site 0158)
Tomball, Texas, 77375
Cotton O'Neil Clinical Research Center ( Site 0095)
Topeka, Kansas, 66606
Lundquist Institute for Biomedical Innovation at Harbor-UCLA Medical Center ( Site 0058)
Torrance, California, 90502
Arcturus Healthcare , PLC, Troy Internal Medicine Research Division ( Site 0003)
Troy, Michigan, 48098
Cardiology Associates of North Mississippi ( Site 0169)
Tupelo, Mississippi, 38801
NextStage Clinical Research - Waco ( Site 0196)
Waco, Texas, 76712
Emerson Clinical Research Institute ( Site 0143)
Washington D.C., District of Columbia, 20009
Cardiovascular Associates of the Delaware Valley ( Site 0162)
Washington Township, New Jersey, 08080
Chase Medical Research, LLC ( Site 0046)
Waterbury, Connecticut, 06708
Velocity Clinical Research, Salt Lake City ( Site 0019)
West Jordan, Utah, 84088
AMR Clinical - Wichita ( Site 0116)
Wichita, Kansas, 67226
Wake Forest Baptist Health-Cardiovascular Medicine ( Site 0142)
Winston-Salem, North Carolina, 27157
Clinical Site Partners LLC, dba CSP Orlando ( Site 0067)
Winter Park, Florida, 32789
North Georgia Clinical Research ( Site 0128)
Woodstock, Georgia, 30189
Cardiology Consultants of Philadelphia Yardley ( Site 0072)
Yardley, Pennsylvania, 19067
Trinity Health-Michigan d/b/a Michigan Heart ( Site 0186)
Ypsilanti, Michigan, 48197
Genesis Healthcare System-Pharmacy Research ( Site 0163)
Zanesville, Ohio, 43701
China58 sites
Baotou Central Hospital-Cardiology ( Site 3436)
Baotou, Inner Mongolia, 014040
Beijing Anzhen Hospital, Capital Medical University-Cardiovascular ( Site 3400)
Beijing, Beijing Municipality, 100029
Beijing Tsinghua Changgung Hospital ( Site 3423)
Beijing, Beijing Municipality, 102218
Jilin Province People's Hospital-Department of Cardiology ( Site 3442)
Changchun, Jilin, 130021
Changsha Central Hospital-Cardiovascular ( Site 3404)
Changsha, Hunan, 410004
The Third Xiangya Hospital of Central South University-Cardiology ( Site 3412)
Changsha, Hunan, 410013
The Third Hospital of Changsha-Cardiovascular department ( Site 3434)
Changsha, Hunan, 410015
Changzhou Second People's Hospital-Cardiology ( Site 3459)
Changzhou, Jiangsu, 213000
The Third People's Hospital of Chengdu (CDTPH) ( Site 3430)
Chengdu, Sichuan, 610014
Chengdu Second Municipal People's Hospital ( Site 3419)
Chengdu, Sichuan, 610021
Chifeng Hospital-Department of Cardiology ( Site 3433)
Chifeng, Inner Mongolia, 024099
The Second Affiliated Hospital of Chongqing Medical University ( Site 3424)
Chongqing, Chongqing Municipality, 400072
Chongqing University Three Gorges Hospital ( Site 3441)
Chongqing, Chongqing Municipality, 404000
Daqing People's Hospital-Cardiology ( Site 3470)
Daqing, Heilongjiang, 163316
The Eighth Affiliated Hospital of Southern Medical University ( Site 3427)
Foshan, Guangdong, 528399
Guangdong Provincial People's Hospital-Cardiology ( Site 3402)
Guangzhou, Guangdong, 510080
Zhujiang Hospital of Southern Medical University ( Site 3415)
Guangzhou, Guangdong, 510280
The Affiliated Hospital of Guizhou Medical University ( Site 3486)
Guiyang, Guizhou, 550004
Hainan General Hospital ( Site 3409)
Haikou, Hainan, 570311
The First Affiliated Hospital, Zhejiang University ( Site 3417)
Hangzhou, Zhejiang, 310003
The first affiliated Hospital of Harbin Medical University-Cardiology ( Site 3406)
Harbin, Heilongjiang, 150001
The Fourth Hospital of Harbin Medical University-Endocrinology department ( Site 3452)
Harbin, Heilongjiang, 150001
Second Affiliated hospital of Anhui Medical University-Cardiology ( Site 3458)
Hefei, Anhui, 230601
Inner Mongolia People's Hospital ( Site 3439)
Hohhot, Inner Mongolia, 010017
Huizhou Municipal Central Hospital ( Site 3467)
Huizhou, Guangdong, 516001
Jiangmen Center Hospital ( Site 3492)
Jiangmen, Guangdong, 529030
The First Affiliated Hospital of Jinzhou Medical University ( Site 3476)
Jinzhou, Liaoning, 121001
Taizhou Hospital of Zhejiang Province-Cardiovascular Department ( Site 3472)
Linhai, Zhejiang, 317000
Linyi People's Hospital ( Site 3468)
Linyi, Shandong, 276003
Lishui Central Hospital ( Site 3455)
Lishui, Zhejiang, 323030
The Third Hospital of Nanchang - Fuhe-cardiology ( Site 3496)
Nanchang, Jiangxi, 330003
The Third Hospital of Nanchang ( Site 3454)
Nanchang, Jiangxi, 330009
The Second Affiliated Hospital of Nanjing Medical University-Cardiology ( Site 3480)
Nanjing, Jiangsu, 210011
Nanyang First People's Hospital ( Site 3469)
Nanyang, Henan, 473000
The Second People's Hospital of Neijiang ( Site 3482)
Neijiang, Sichuan, 641099
Pingxiang People's Hospital-Cardiology ( Site 3473)
Pingxiang, Jiangxi, 337055
The Third Affiliated Hospital of Qiqihar Medical University ( Site 3465)
Qiqihar, Heilongjiang, 161000
Shanghai Tongji Hospital ( Site 3431)
Shanghai, Shanghai Municipality, 200065
Shanghai General Hospital ( Site 3479)
Shanghai, Shanghai Municipality, 200080
Shanghai East Hospital ( Site 3485)
Shanghai, Shanghai Municipality, 200120
The People's Hospital of Liaoning Province-Cardiology ( Site 3453)
Shenyang, Liaoning, 110016
The University of Hong Kong-Shenzhen Hospital-Cardiovascular department ( Site 3414)
Shenzhen, Guangdong, 518053
Siping Central People's Hospital-Cardiovascular Department ( Site 3408)
Siping, Jilin, 136000
Suining Central Hospital ( Site 3487)
Suining, Sichuan, 629000
Shanxi Cardiovascular Hospital ( Site 3462)
Taiyuan, Shaanxi, 030024
Tianjin People' s Hospital-Cardiology ( Site 3425)
Tianjin, Tianjin Municipality, 300121
Tianjin Fourth Centre Hospital-Department of Cardiology ( Site 3456)
Tianjin, Tianjin Municipality, 300140
Pu'ai Hospital of Wuhan City ( Site 3451)
Wuhan, Hubei, 430030
Renmin Hospital of Wuhan University ( Site 3464)
Wuhan, Hubei, 430060
The First Affiliated Hospital of Xi'an Jiaotong University ( Site 3420)
Xi'an, Shaanxi, 710061
Shaanxi provincial people's hospital ( Site 3421)
Xi'an, Shaanxi, 710068
Xianyang Hospital of Yan'an University ( Site 3435)
Xianyang, Shaanxi, 712000
The Affiliated Hospital of Xuzhou Medical College ( Site 3403)
Xuzhou, Jiangsu, 221000
Northern Jiangsu People's Hospital ( Site 3405)
Yangzhou, Jiangsu, 225001
General Hospital of Ningxia Medical University ( Site 3478)
Yinchuan, Ningxia, 750004
The First People's Hospital of Yueyang-Cardiovascular department ( Site 3448)
Yueyang, Hunan, 414000
Affiliated Hospital of Jiangsu University-Cardiology Department ( Site 3481)
Zhenjiang, Jiangsu, 212001
Zibo Municipal Hospital ( Site 3474)
Zibo, Shandong, 255400
Japan38 sites
Tokyonishi Tokushukai Hospital ( Site 3530)
Akishima, Tokyo, 196-0003
Fujisawa City Hospital ( Site 3522)
Fujisawa, Kanagawa, 251-8550
Saiseikai Fukuoka General Hospital ( Site 3536)
Fukuoka, 810-0001
Fukuoka University Hospital ( Site 3502)
Fukuoka, 814-0180
Japanese Red Cross Fukuoka Hospital ( Site 3528)
Fukuoka, 815-8555
Minamino Cardiovascular Hospital ( Site 3546)
Hachiōji, Tokyo, 192-0918
Hanyu General Hospital ( Site 3504)
Hanyū, Saitama, 348-8505
Affiliated Central Clinic of Higashiyamato Hospital ( Site 3533)
Higashiyamato, Tokyo, 207-0014
Hyogo Prefectural Harima-Himeji General Medical Center ( Site 3514)
Himeji, Hyōgo, 670-8560
Tokai University Hospital ( Site 3500)
Isehara, Kanagawa, 259-1193
Nakamura Cardiovascular Clinic ( Site 3529)
Itoshima, Fukuoka, 819-1104
Shonan Kamakura General Hospital ( Site 3516)
Kamakura, Kanagawa, 247-8533
Fukuoka Tokushukai Hospital ( Site 3511)
Kasuga, Fukuoka, 816-0864
Kokura Memorial Hospital ( Site 3521)
Kitakyushu, Fukuoka, 802-8555
Kumamoto University Hospital ( Site 3501)
Kumamoto, 860-8556
Saiseikai Kumamoto Hospital ( Site 3515)
Kumamoto, 861-4193
Kyoto Okamoto Memorial Hospital ( Site 3524)
Kuse-gun Kumiyama-cho, Kyoto, 613-0034
Kyoto City Hospital ( Site 3542)
Kyoto, 604-8845
Seikeikai Medical Corporation New Tokyo Heart Clinic ( Site 3537)
Matsudo, Chiba, 271-0077
Nagasaki Harbor Medical Center ( Site 3527)
Nagasaki, 850-8555
Nagoya Kyoritsu Hospital ( Site 3531)
Nagoya, Aichi-ken, 454-0933
Chubu Rosai Hospital ( Site 3507)
Nagoya, Aichi-ken, 455-8530
Go Neurosurgical Clinic ( Site 3534)
Nakagawa, Fukuoka, 811-1244
Okayama City General Medical Center Okayama City Hospital ( Site 3508)
Okayama, 700-8557
National Hospital Organization Okayama Medical Center ( Site 3512)
Okayama, 7011192
National Hospital Organization Nagasaki Medical Center ( Site 3505)
Ōmura, Nagasaki, 856-8562
National Hospital Organization Osaka National Hospital ( Site 3503)
Osaka, 540-0006
Saga-Ken Medical Centre Koseikan ( Site 3543)
Saga, Saga-ken, 840-8571
Sanai Hospital - Saitama ( Site 3532)
Saitama, 332-0012
Saitama City Hospital ( Site 3535)
Saitama, 336-8522
Matsuda Cardiovascular Clinic ( Site 3526)
Sapporo, Hokkaido, 003-0026
TAKAMATSU Red Cross Hospital ( Site 3506)
Takamatsu, Kagawa-ken, 760-0017
Kagawa Prefectural Central Hospital ( Site 3538)
Takamatsu, Kagawa-ken, 760-8557
Machida Municipal Hospital ( Site 3545)
Tokyo, 194-0023
Toyota Kosei Hospital ( Site 3519)
Toyota, Aichi-ken, 470-0396
Toyota Memorial Hospital ( Site 3539)
Toyota, Aichi-ken, 471-8513
Tsukuba Medical Center Hospital ( Site 3540)
Tsukuba, Ibaraki, 305-8558
Uji-Tokushukai Medical Center ( Site 3509)
Uji, Kyoto, 611-0041
Netherlands35 sites
Noordwest Ziekenhuisgroep-Research Cardiology ( Site 1914)
Alkmaar, North Holland, 1815 JD
Ziekenhuisgroep Twente, locatie Almelo-Cardioresearch ZGT ( Site 1919)
Almelo, Overijssel, 7609 PP
Meander Medisch Centrum ( Site 1933)
Amersfoort, Utrecht, 3813 TZ
Ziekenhuis Amstelland-Cardiologie ( Site 1920)
Amstelveen, North Holland, 1186AM
Onze Lieve Vrouwe Gasthuis ( Site 1922)
Amsterdam, North Holland, 1051 AC
Amsterdam UMC, locatie AMC-Vascular Medicine Clin Trial Unit ( Site 1926)
Amsterdam, North Holland, 1105 AZ
Gelre Ziekenhuis ( Site 1907)
Apeldoorn, Gelderland, 7334 DZ
Amphia Ziekenhuis, locatie Breda Molengracht-Research cardiology ( Site 1903)
Breda, North Brabant, 4818 CK
Reinier de Graaf Ziekenhuis, locatie Delft-Research Department Cardiology ( Site 1915)
Delft, South Holland, 2625 AD
Slingeland Ziekenhuis ( Site 1941)
Doetinchem, Gelderland, 7009 BL
Albert Schweitzer Ziekenhuis, locatie Dordwijk ( Site 1901)
Dordrecht, South Holland, 3318 AT
Ziekenhuis Gelderse Vallei ( Site 1939)
Ede, Gelderland, 6716 RP
Catharina Ziekenhuis ( Site 1934)
Eindhoven, North Brabant, 5623 EJ
Treant, locatie Scheper Ziekenhuis ( Site 1918)
Emmen, Drenthe, 7824 AA
Admiraal de Ruyter Ziekenhuis, locatie Goes ( Site 1900)
Goes, Zeeland, 4462 RA
Groene Hart Ziekenhuis-Research Cardiologie ( Site 1932)
Gouda, South Holland, 2803 HH
Martini Ziekenhuis ( Site 1940)
Groningen, 9728 NT
Ziekenhuis St. Jansdal ( Site 1917)
Harderwijk, Gelderland, 3844 DG
Elkerliek Ziekenhuis ( Site 1938)
Helmond, North Brabant, 5707 HA
Tergooiziekenhuizen, locatie Hilversum ( Site 1929)
Hilversum, North Holland, 1213 XZ
Treant, locatie Ziekenhuis Bethesda-Bethesda Diabetes Research Center ( Site 1930)
Hoogeveen, Drenthe, 7909 AA
Dijklander Ziekenhuis ( Site 1936)
Hoorn, North Holland, 1624 NP
Medische Centrum Leeuwarden ( Site 1935)
Leeuwarden, Provincie Friesland, 8934 AD
Leids Universitair Medisch Centrum ( Site 1924)
Leiden, South Holland, 2333 ZA
Alrijne Ziekenhuis, locatie Leiderdorp ( Site 1902)
Leiderdorp, South Holland, 2353 GA
Radboudumc-Cardiology ( Site 1925)
Nijmegen, Gelderland, 6525 GA
Bravis Ziekenhuis, locatie Roosendaal ( Site 1905)
Roosendaal, North Brabant, 4708 AE
Erasmus Medisch Centrum, Centrumlocatie ( Site 1943)
Rotterdam, South Holland, 3015 GD
Ikazia Ziekenhuis ( Site 1911)
Rotterdam, South Holland, 3083 AN
Antonius Ziekenhuis, locatie D&A Research and Genetics ( Site 1928)
Sneek, Provincie Friesland, 8601 ZR
Haga Ziekenhuis locatie Leyweg ( Site 1909)
The Hague, South Holland, 2545 AA
Ziekenhuis Rivierenland-Remati ( Site 1916)
Tiel, Gelderland, 4002 WP
VieCuri Medisch Centrum, locatie Venlo-Cardiology ( Site 1923)
Venlo, Limburg, 5912 BL
Zaans Medisch Centrum ( Site 1942)
Zaandam, North Holland, 1502 DV
Gelre Ziekenhuizen ( Site 1908)
Zutphen, Gelderland, 7207 AE
Poland32 sites
Trial Medica ( Site 2122)
Bialystok, Podlaskie Voivodeship, 15-481
Polsko-Amerykańskie Kliniki Serca II Oddział Kardiologiczny ( Site 2140)
Bielsko-Biala, Silesian Voivodeship, 43-316
NZOZ Centrum Medyczne KERmed ( Site 2121)
Bydgoszcz, Kuyavian-Pomeranian Voivodeship, 85-231
Centrum Medyczne Pratia Bydgoszcz-Centrum Medyczne Pratia Bydgoszcz ( Site 2125)
Bydgoszcz, Kuyavian-Pomeranian Voivodeship, 85-796
Polsko-Amerykańskie Kliniki Serca PAKS Małopolskie Centrum Sercowo-Naczyniowe ( Site 2141)
Chrzanów, Lesser Poland Voivodeship, 32-500
Polsko-Amerykańskie Kliniki Serca ( Site 2145)
Dąbrowa Górnicza, Silesian Voivodeship, 41-300
Poradnia Kardiologiczna KOS-Zawal ( Site 2104)
Elblag, Warmian-Masurian Voivodeship, 82-300
Uniwersyteckie Centrum Kliniczne ( Site 2148)
Gdansk, Pomeranian Voivodeship, 80-214
Indywidualna Specjalistyczna Praktyka Lekarska w Dziedzinie Kardiologii Lek. med. Krzysztof Cymerman ( Site 2112)
Gdynia, Pomeranian Voivodeship, 81-157
Gabinet Kardiologiczno Internistyczny ( Site 2111)
Gdynia, Pomeranian Voivodeship, 81-472
AMEDS CLINICAL RESEARCH ( Site 2166)
Grodzisk Mazowiecki, Masovian Voivodeship, 05-825
SPZOZ im. Jana Pawła II w Grodzisku Mazowieckim ( Site 2155)
Grodzisk Mazowiecki, Masovian Voivodeship, 05-825
Centrum Medyczne Pratia Katowice ( Site 2108)
Katowice, Silesian Voivodeship, 40-081
Clinical Medical Research ( Site 2102)
Katowice, Silesian Voivodeship, 40-156
Maopolskie Centrum Kliniczne ( Site 2113)
Krakow, Lesser Poland Voivodeship, 30-149
Beata Miklaszewicz & Dariusz Dabrowski CARDIAMED s.j. ( Site 2118)
Legnica, Lower Silesian Voivodeship, 59-220
SOMED CR ( Site 2160)
Lodz, Łódź Voivodeship, 90-368
Instytut Centrum Zdrowia Matki Polki ( Site 2165)
Lodz, Łódź Voivodeship, 93-338
NZOZ Twoja Przychodnia ( Site 2105)
Lublin, Lublin Voivodeship, 20-857
Solumed Centrum Medyczne ( Site 2123)
Poznan, Greater Poland Voivodeship, 60-529
Clinical Research Center Spółka z ograniczoną odpowiedzialnością MEDIC-R Sp.k ( Site 2150)
Poznan, Greater Poland Voivodeship, 61-731
Centrum Medyczne Medyk ( Site 2101)
Rzeszów, Podkarpackie Voivodeship, 35-055
Velocity Skierniewice Sp. z o. o. ( Site 2114)
Skierniewice, Łódź Voivodeship, 96-100
NZOZ Sopockie Centrum Badan Kardiologicznych Pro Cordis Pawel Miekus ( Site 2130)
Sopot, Pomeranian Voivodeship, 81-717
Centrum Szybkiej Diagnostyki Kardiologicznej "Kardiomed" M. Żabówka E. Żabówka ( Site 2119)
Tarnów, Lesser Poland Voivodeship, 33-100
Private Practice - Dr. Robert Witek-Ośrodek Badań Klinicznych "METABOLICA" Lek. Robert Witek ( Site 2162)
Tarnów, Lesser Poland Voivodeship, 33-100
MICS Centrum Medyczne Torun ( Site 2159)
Torun, Kuyavian-Pomeranian Voivodeship, 87-100
Polsko-Amerykańskie Kliniki Serca ( Site 2142)
Tychy, Silesian Voivodeship, 43-100
Szpital Grochowski im. dr med. Rafała Masztaka SPZOZ ( Site 2139)
Warsaw, Masovian Voivodeship, 04-073
Narodowy Inst. Kardiologii Stefana kardynala Wyszynskiego-Inst. Badawczy.Centr.Wsparcia Badan Klinic ( Site 2132)
Warsaw, Masovian Voivodeship, 04-628
Indywidualna Specjalistyczna Praktyka Lekarska dr n.med. Andrzej Tomasik ( Site 2146)
Zabrze, Silesian Voivodeship, 41-800
Polsko Amerykanskie Kliniki Serca - Zgierskie ( Site 2144)
Zgierz, Łódź Voivodeship, 95-100
Germany30 sites
Klinikum am Plattenwald ( Site 1590)
Bad Friedrichshall, Baden-Wurttemberg, 74177
Kerckhoff-Klinik ( Site 1599)
Bad Nauheim, Hesse, 61231
Praxis Rankestrasse ( Site 1548)
Berlin, 10789
Charite Universitätsmedizin Berlin Campus Benjamin Franklin ( Site 1568)
Berlin, 12203
DRK Kliniken Berlin - Köpenick ( Site 1580)
Berlin, 12559
Synexus Berlin Clinical Research Centre ( Site 1585)
Berlin, 12627
Jüdisches Krankenhaus Berlin ( Site 1595)
Berlin, 13347
Klinikum Bielefeld Mitte ( Site 1561)
Bielefeld, North Rhine-Westphalia, 33604
Zentrum fur klinische Forschung - Köln ( Site 1573)
Cologne, North Rhine-Westphalia, 51069
St.-Johannes-Hospital Dortmund-Clinic of Internal medicine I ( Site 1567)
Dortmund, North Rhine-Westphalia, 44137
Zentrum fuer klinische Pruefungen in der Facharztzentrum Dresden Neustadt GbR ( Site 1597)
Dresden, Saxony, 01099
Universitaetsklinikum Carl Gustav Carus Dresden-Universitätsstudienzentrum für Stoffwechselerkranku ( Site 1549)
Dresden, Saxony, 01307
Die Bocholder Hausärzte ( Site 1587)
Essen, North Rhine-Westphalia, 45355
Klinisches Forschungszentrum Dr. Hagemann am Hausarztzentrum am Germaniaplatz ( Site 1554)
Essen, North Rhine-Westphalia, 45355
Unterfrintroper Hausarztzentrum Klinische Forschung ( Site 1550)
Essen, North Rhine-Westphalia, 45359
Synexus Clinical Research GmbH Synexus Frankfurt Clinical Research Centre ( Site 1592)
Frankfurt am Main, Hesse, 60313
ClinPhenomics CVC GmbH ( Site 1593)
Frankfurt am Main, Hesse, 60596
Universitaetsklinikum Hamburg-Eppendorf ( Site 1556)
Hamburg, 20246
Cardiologicum Hamburg ( Site 1596)
Hamburg, 22041
Siteworks GmbH ( Site 1552)
Hanover, Lower Saxony, 30449
Siteworks GmbH - Heidelberg ( Site 1546)
Heidelberg, Baden-Wurttemberg, 69115
Hausarzt- und Diabetologische Schwerpunktpraxis Hohenmölsen - Weiβenfels ( Site 1574)
Hohenmölsen, Saxony-Anhalt, 06679
Kardiopraxis Schirmer Kaiserslautern ( Site 1576)
Kaiserslautern, Rhineland-Palatinate, 67655
Synexus Leipzig Clinical Research Centre ( Site 1591)
Leipzig, Saxony, 04103
ze:ro ARZTPRAXEN-Ze:ro Praxen ( Site 1583)
Mannheim, Baden-Wurttemberg, 68165
Kardiologische Gemeinschaftspraxis ( Site 1564)
Nuremberg, Bavaria, 90402
Studienzentrum Brinkum - Torsten Drescher & Dr. Lars Pohlmeier ( Site 1557)
Stuhr, Lower Saxony, 28816
Siteworks GmbH - Völklingen ( Site 1553)
Völklingen, Saarland, 66333
Gemeinschaftspraxis Dr. med. Josef und Wilma Großkopf ( Site 1547)
Wallerfing, Bavaria, 94574
Forschungszentrum Ruhr ( Site 1586)
Witten, North Rhine-Westphalia, 58455
Mexico30 sites
Centro de Atención e Investigación Clínica ( Site 1010)
Aguascalientes, 20129
Centro de Investigación Cardiometabólica de Aguascalientes ( Site 1034)
Aguascalientes, 20230
Fundación Cardiovascular de Aguascalientes A.C. ( Site 1020)
Aguascalientes, 20230
ICARO Investigaciones en Medicina ( Site 1005)
Chihuahua City, 31000
Centro de Estudios de Investigacion Metabolicos y Cardiovasculares, S.C. ( Site 1006)
Ciudad Madero, Tamaulipas, 89440
Centro de Investigación y Gastroenterología ( Site 1002)
Cuauhtémoc, 06700
CHRISTUS Centro de Excelencia en Investigación (Norte) ( Site 1032)
General Escobedo, Nuevo León, 66055
Instituto Jalisciense de Investigacion en Diabetes y Obesidad-Endocrinology ( Site 1007)
Guadalajara, Jalisco, 04460
Unidad de Investigaci�n Cl�nica Cardiometabolica de Occident-Unidad de Investigación Clínica Cardio ( Site 1015)
Guadalajara, Jalisco, 44150
Cardiocent de Guadalajara S.C.-cardiocent de guadalajara SC ( Site 1001)
Guadalajara, Jalisco, 44160
Centro de Investigación Médico Biológica y Terapia Avanzada ( Site 1021)
Guadalajara, Jalisco, 44650
Bio Investigación AMARC, S.C. ( Site 1013)
Gustavo Adolfo Madero, Mexico City, 07800
Morales Vargas Centro de Investigacion ( Site 1029)
León, Guanajuato, 37000
Centro Multidisciplinario para el Desarrollo Especializado de la Investigacion Clinica en Yucatan ( Site 1017)
Mérida, Yucatán, 97130
Instituto Nacional de Cardiologia Ignacio Chavez-Endocrinology ( Site 1018)
México, 14080
HOSPITAL GENERAL DE MEXICO DR. EDUARDO LICEAGA-Farmacologia Clinica ( Site 1033)
Mexico City, Mexico City, 06720
Centro de Imagen y Tecnología en Intervención Cardiovascular-Research ( Site 1041)
Mexico City, Mexico City, 10400
Clínica Integral del Paciente Diabético y Obeso ( Site 1016)
Mexico City, Mexico City, 11850
Medica Sur-Clinica de Enfermedades Digestivas y Obesidad ( Site 1024)
Mexico City, Mexico City, 14050
Instituto Nacional de Ciencias Medicas y Nutricion Salvador Zubiran ( Site 1012)
Mexico City, Mexico City, 14080
Hospital Universitario "Dr. Jose Eleuterio Gonzalez"-Endocrinologia ( Site 1025)
Monterrey, Nuevo León, 64460
Unidad biomedica avanzada monterrey-Clinical Trials ( Site 1000)
Monterrey, Nuevo León, 64460
Centro de investigación y control metabólico ( Site 1003)
Monterrey, Nuevo León, 66465
Oaxaca Site Management Organization S.C. ( Site 1004)
Oaxaca City, 68000
Centro de Investigacion Clinica de Oaxaca ( Site 1011)
Oaxaca City, 68020
Grupo Ollin Care ( Site 1023)
Pachuca, Hidalgo, 42000
Centro de Investigacion Cardiovascular y Metabólica ( Site 1027)
Tijuana, Estado de Baja California, 22500
Instituto Veracruzano en Investigación Clínica S.C. ( Site 1035)
Veracruz, 91851
Arké SMO S.A de C.V ( Site 1026)
Veracruz, 91900
Centro de Investigacion Medica de Occidente, S.C.-Departamento de Centro de Investigacion Medica d ( Site 1022)
Zapopan, Jalisco, 44260
South Africa24 sites
Tiervlei Trial Centre-Clinical ( Site 2205)
Bellville, Cape Town, Western Cape, 7530
IATROS INTERNATIONAL ( Site 2206)
Bloemfontein, Free State, 9301
Helderberg Research Institute ( Site 2231)
Cape Town, Western Cape, 7130
TREAD Research ( Site 2212)
Cape Town, Western Cape, 7500
Enhancing Care Foundation-ECF research pharmacy ( Site 2213)
Durban, KwaZulu-Natal, 4052
Private Practice - Dr. Neyaseelan Gounden ( Site 2207)
Durban, KwaZulu-Natal, 4093
Excellentis Clinical Trial Consultants ( Site 2221)
George, Western Cape, 6529
TASK Eden ( Site 2227)
George, Western Cape, 6529
Lenasia Clinical Trial Centre - Johannesburg ( Site 2266)
Johannesburg, Gauteng, 1827
Bara Cardiology Research ( Site 2258)
Johannesburg, Gauteng, 2013
Helen Joseph Hospital-Clinical HIV Research Unit ( Site 2230)
Johannesburg, Gauteng, 2092
Futurex Clinical. Dr Soraya Cassimjee INC ( Site 2269)
Johannesburg, Gauteng, 2192
Netcare Sunninghill Hospital ( Site 2257)
Johannesburg, Gauteng, 2196
Midrand Medical Centre ( Site 2202)
Midrand, Gauteng, 1685
Zinakekele Medicall Centre ( Site 2225)
Moloto, Gauteng, 1029
Be Part Yoluntu Centre ( Site 2209)
Paarl, Western Cape, 7626
Paarl Research Centre ( Site 2214)
Paarl, Western Cape, 7646
Tsitsikamma Clinical Research Initiative (TCRI) ( Site 2226)
Plettenberg Bay, Western Cape, 6600
Phoenix Pharma ( Site 2204)
Port Elizabeth, Eastern Cape, 6001
Clinical Trial Systems ( Site 2210)
Pretoria, Gauteng, 0186
Sefako Makgatho Health Sciences University ( Site 2268)
Pretoria, Gauteng, 0204
Jongaie Research ( Site 2211)
Pretoria West, Gauteng, 0183
Wits Clinical Research ( Site 2220)
Soweto, Gauteng, 2013
Clinical Projects Research ( Site 2265)
Worcester, Western Cape, 6850
Spain23 sites
Hospital Universitario Fundacion ALcorcon ( Site 2353)
Alcorcón, Madrid, Comunidad de, 28922
Hospital Universitari Vall d'Hebron ( Site 2342)
Barcelona, Catalonia, 08035
Corporació de Salut del Maresme i la Selva ( Site 2365)
Calella, Barcelona, 08370
Vithas Hospital Sevilla-Unidad de Salud Metabólica. Diabetes y Obesidad ( Site 2349)
Castilleja de la Cuesta, Sevilla, 41950
EAP Osona Sud - Alt Congost S.L.P ( Site 2311)
Centelles, Catalonia, 08540
Hospital Universitario Reina Sofia-Medicina Interna ( Site 2362)
Córdoba, Andalusia, 14004
Hospital Clínico Universitario Virgen de la Arrixaca-CARDIOLOGÍA ( Site 2328)
El Palmar, Murcia, Murcia, Region de, 30120
Hospital Universitari de Bellvitge-Unitat de Lipids i Risc Vascular ( Site 2327)
L'Hospitalet de Llobregat, Catalonia, 08907
Complejo Asistencial Universitario de León - Hospital de León ( Site 2339)
León, Leon, 24071
Hospital Universitario Ramón y Cajal ( Site 2337)
Madrid, Madrid, Comunidad de, 28034
Hospital Universitario La Paz ( Site 2333)
Madrid, Madrid, Comunidad de, 28046
Hospital La Luz ( Site 2366)
Madrid, 28003
Hospital La Princesa ( Site 2334)
Madrid, 28006
Hospital Clinico San Carlos-Cardiology ( Site 2325)
Madrid, 28040
HOSPITAL UNIVERSITARIO PUERTA DE HIERRO MAJADAHONDA ( Site 2348)
Majadahonda, Madrid, Comunidad de, 28222
Hospital Universitario Virgen de la Victoria-UGC Endocrinologia y nutricion ( Site 2323)
Málaga, Andalusia, 29010
HOSPITAL UNIVERSITARIO QUIRONSALUD MADRID-Endocrinologia y Nutrición ( Site 2344)
Pozuelo de Alarcón, Madrid, 28223
CHUS - Hospital Clinico Universitario-Cardiology - Clinical Research Unit ( Site 2320)
Santiago de Compostela, La Coruna, 15706
Hospital Universitario Virgen de Valme-Internal Medicine ( Site 2336)
Seville, Andalusia, 41014
Hospital Universitari Joan XXIII de Tarragona ( Site 2350)
Tarragona, 43005
Hospital Universitario de Torrevieja ( Site 2351)
Torrevieja, Alicante, 03186
Hospital Universitari i Politecnic La Fe ( Site 2340)
Valencia, Valencia, 46026
HOSPITAL CLINICO DE VALENCIA-CARDIOLOGY ( Site 2321)
Valencia, Valenciana, Comunitat, 46010
Argentina21 sites
CIPREC-CIPREC Sede Arenales ( Site 0624)
Buenos Aires, Buenos Aires F.D., C1061AAS
Fundación favaloro para la Docencia e Investigación Médica ( Site 0606)
Buenos Aires, Buenos Aires F.D., C1093AAS
Centro Medico Dra. Laura Maffei- Investigacion Clinica Aplicada ( Site 0604)
Buenos Aires, Buenos Aires F.D., C1425AGC
Fundación Respirar ( Site 0610)
Buenos Aires, Buenos Aires F.D., C1426ABP
Sanatorio Finochietto ( Site 0626)
Buenos Aires, C1187AAN
CEDIC ( Site 0612)
CABA, Buenos Aires, C1060ABN
CEMEDIC ( Site 0609)
CABA, Buenos Aires, C1407GTL
Centro de Investigaciones Metabólicas (CINME) ( Site 0620)
CABA, C1056ABI
Instituto Médico DAMIC ( Site 0603)
Córdoba, Córdoba Province, 5003DCE
Instituto de Cardiología "Juana F. Cabral"-Cardiología ( Site 0608)
Corrientes, W3400AMZ
Framingham Centro Médico ( Site 0625)
La Plata, Buenos Aires, B1902COS
CIMeL ( Site 0613)
Lanus, Buenos Aires, B1824KAJ
Instituto de Investigaciones Clínicas Mar del Plata ( Site 0605)
Mar del Plata, Buenos Aires, B7600FZO
DIM Clínica Privada ( Site 0627)
Ramos Mejía, Buenos Aires, B1704ETD
Instituto de Investigaciones Clinicas Rosario ( Site 0602)
Rosario, Santa Fe Province, S2000CVD
Fundacion Estudios Clinicos ( Site 0619)
Rosario, Santa Fe Province, S2000DEJ
Laboratorio de Hemostasia y Trombosis ( Site 0623)
Rosario, Santa Fe Province, S2000DTB
Go Centro Medico San Nicolás ( Site 0621)
San Nicolás de los Arroyos, Buenos Aires, 2900
Clínica de Nefrología, Urología y Enfermedades Cardiovasculares ( Site 0615)
Santa Fe, Santa Fe Province, S3000BPJ
Centro de Investigaciones Clinicas del Litoral ( Site 0607)
Santa Fe, 3000
Instituto de Investigaciones Clinicas Zarate ( Site 0600)
Zárate, Buenos Aires, B2800DGH
Brazil18 sites
Centro de Pesquisa Clinica do Coracao ( Site 0713)
Aracaju, Sergipe, 49055-530
Hospital Universitário São Francisco de Assis - Bragança Paulista ( Site 0725)
Bragança Paulista, São Paulo, 12916-542
Centro de Pesquisa Clinica do Brasil ( Site 0719)
Brasília, Federal District, 71625-175
Hospital Angelina Caron ( Site 0702)
Campina Grande do Sul, Paraná, 83430-000
Instituto de Pesquisa clinica de Campinas ( Site 0706)
Campinas, São Paulo, 13060-080
Hospital do Rocio ( Site 0721)
Campo Largo, Paraná, 83606-177
Hospital Universitário ( Site 0723)
Canoas, Rio Grande do Sul
Centro de Pesquisas em Diabetes e Doenças Endócrino-Metabólicas ( Site 0728)
Fortaleza, Ceará, 60430-350
Universidade Federal de Goias ( Site 0717)
Goiânia, Goiás, 74605-020
Instituto de Cardiologia do Rio Grande do Sul ( Site 0704)
Porto Alegre, Rio Grande do Sul, 90620001
Hospital Mae de Deus ( Site 0716)
Porto Alegre, Rio Grande do Sul, 90880-480
Hospital Nossa Senhora da Conceição-FZ PESQUISA E SERVIÇOS EM CARDIOLOGIA CLÍNICA LTDA ( Site 0712)
Porto Alegre, Rio Grande do Sul, 91350-280
IBPClin - Instituto Brasil de Pesquisa Clínica ( Site 0715)
Rio de Janeiro, 20241-180
Hospital e Maternidade Christóvão da Gama (HMCG) ( Site 0724)
Santo André, São Paulo, 09020-270
Fundação Faculdade Regional de Medicina de São José do Rio Preto ( Site 0707)
São José do Rio Preto, São Paulo, 15090000
Instituto Dante Pazzanese de Cardiology-Fundação Adib Jatene ( Site 0708)
São Paulo, São Paulo, 04012-909
CEPIC - Centro Paulista de Investigação Clínica ( Site 0710)
São Paulo, São Paulo, 04266-010
Integral Pesquisa e Ensino ( Site 0709)
Votuporanga, São Paulo, 15500-269
Colombia18 sites
Ciensalud Ips S A S ( Site 0903)
Barranquilla, Atlántico, 08001
Clinica de la Costa S.A.S. ( Site 0902)
Barranquilla, Atlántico, 080020
IPS Centro Científico Asistencial S.A.S ( Site 0900)
Barranquilla, Atlántico, 080020
Sociedad de Cirugía de Bogotá - Hospital de San Jose ( Site 0920)
Bogota, Cundinamarca, 1100100
Fundacion Santa Fe de Bogota ( Site 0916)
Bogotá, Cundinamarca, 110111
Solano & Terront Servicios Medicos - UNIENDO ( Site 0915)
Bogotá, Cundinamarca, 110221
Salud SURA Calle 100 ( Site 0918)
Bogotá, Cundinamarca, 110231
Fundación Valle del Lili ( Site 0904)
Cali, Valle del Cauca Department, 760032
Centro de Investigaciones Clinicas SAS ( Site 0912)
Cali, Valle del Cauca Department, 760036
Mediservis del Tolima IPS S.A.S ( Site 0914)
Ibague, Tolima Department, 730006
IPS Médicos Internistas de Caldas ( Site 0905)
Manizales, Caldas Department, 170004
Fundación Centro de Investigación Clínica CIC ( Site 0906)
Medellín, Antioquia, 050021
Salud SURA Industriales ( Site 0917)
Medellín, Antioquia, 50021
Rodrigo Botero S.A.S ( Site 0901)
Medellín, Antioquia, 50030
IMAT S.A.S ( Site 0907)
Montería, Departamento de Córdoba, 230002
Fundación Cardiovascular de Colombia ( Site 0911)
Piedecuesta, Santander Department, 681017
Instituto Cardiovascular del Cesar S.A ( Site 0919)
Valledupar, Cesar Department, 200001
Healthy Medical Center S.A.S ( Site 0913)
Zipaquirá, Cundinamarca, 250252
Israel18 sites
Barzilai Medical Center ( Site 1713)
Ashkelon, 7830604
Soroka Medical Center ( Site 1715)
Beersheba, 8410101
Hillel Yaffe Medical Center ( Site 1705)
Hadera, 3810101
Linn Medical Center ( Site 1711)
Haifa, 3100000
Rambam Health Care Campus ( Site 1702)
Haifa, 3109601
Rambam Health Care Campus ( Site 1718)
Haifa, 3109601
Institute of Diabetes, Technology and Research - Clalit Health ( Site 1701)
Herzliya, 4630945
Clalit health Services - Holon Medical Center ( Site 1721)
Holon, 5840608
Shaare Zedek Medical Center ( Site 1710)
Jerusalem, 9103102
Hadassah Medical Center ( Site 1706)
Jerusalem, 9112001
Hadassah Medical Center ( Site 1709)
Jerusalem, 9112001
Clalit Health Services - Majd Al-Krum Clinic ( Site 1722)
Majd el Kurūm, 2019000
Galilee Medical Center ( Site 1723)
Nahariya, 2210001
Rabin Medical Center ( Site 1720)
Petah Tikva, 4941 492
Rabin Medical Center ( Site 1703)
Petah Tikva, 4941492
Sheba Medical Center ( Site 1708)
Ramat Gan, 5265601
Kaplan Medical Center ( Site 1724)
Rehovot, 7661041
Clalit Health Services - Sakhnin Community Clinic-Research Unit ( Site 1700)
Sakhnin, 3081000
Hungary17 sites
Lausmed Egészségügyi Szolgáltató ( Site 1621)
Baja, Bács-Kiskun county, 6500
DRC Gyógyszervizsgáló Központ ( Site 1609)
Balatonfüred, Veszprém megye, 8230
Private Practice - Dr. Lakatos Ferenc ( Site 1618)
Békéscsaba, Bekes County, 5600
Zuglói Egészségügyi Szolgálat ( Site 1613)
Budapest, Zala County, 1148
Óbudai Egészségügyi Centrum ( Site 1622)
Budapest, 1036
Gottsegen György Országos Kardiovaszkuláris Intézet ( Site 1605)
Budapest, 1096
Semmelweis Egyetem-Városmajori Szív- és Érgyógyászati Klinika ( Site 1601)
Budapest, 1122
Medoc Egészégközpont - Lehel ( Site 1615)
Budapest, 1134
Cardiogeneral Egészségügyi Kft. ( Site 1610)
Budapest, 1141
Belinus Orvosi és Számitástechnikai Bt ( Site 1608)
Debrecen, Hajdú-Bihar
Debreceni Egyetem Klinikai Kozpont-Belgyógyászati Klinika (Anyagcsere Tanszék) ( Site 1607)
Debrecen, 4032
Óbudai Egészségügyi Centrum - Kaposvár Site ( Site 1625)
Kaposvár, Somogy County, 7400
Borbánya Praxis-Private practice ( Site 1606)
Nyíregyháza, Borbánya, Szabolcs-Szatmár-Bereg, 4405
CoroMed ( Site 1612)
Pécs, Pecs, 7623
Szegedi Tudományegyetem Szent-Györgyi Albert Klinikai Központ-Belgyógyászati Klinika ( Site 1617)
Szeged, Csongrád megye, 6725
Fejér Megyei Szent György Egyetemi Oktató Kórház-2nd Department of Internal Medicine ( Site 1611)
Székesfehérvár, Fejér, 8000
Óbudai Egészségügyi Centrum - Zalaegerszeg ( Site 1624)
Zalaegerszeg, 8900
Italy17 sites
Azienda Socio Sanitaria Territoriale Papa Giovanni XXIII-Cardiologia 1 ( Site 1817)
Bergamo, Lombardy, 20127
Azienda Socio Sanitaria Territoriale degli Spedali Civili di Brescia ( Site 1820)
Brescia, Lombardy, 25123
Azienda Ospedaliero Universitaria di Ferrara ( Site 1816)
Cona, Ferrara, 44124
ASST DI LECCO ( Site 1814)
Lecco, 23900
Centro Cardiologico Monzino ( Site 1804)
Milan, Milano, 20138
ASST Grande Ospedale Metropolitano Niguarda-Unità Ricerche Cliniche della Cardiologia 4 ( Site 1811)
Milan, Milano, 20162
Policlinico di Monza centro diabetologia e malattie metaboliche ( Site 1806)
Monza, Monza E Brianza, 20052
University of Naples Federico II ( Site 1805)
Naples, 80131
A.O.U. Policlinico Paolo Giaccone ( Site 1815)
Palermo, Sicily, 90129
Azienda Ospedaliero Universitaria di Parma ( Site 1813)
Parma, 43126
Fondazione IRCCS Policlinico San Matteo-Cardiology ( Site 1802)
Pavia, 27100
Fondazione Policlinico Universitario Campus Bio-Medico ( Site 1818)
Rome, Lazio, 00128
Fondazione Policlinico Tor Vergata ( Site 1809)
Rome, Lazio, 00133
AOU Policlinico Umberto I-Dipartimento di Scienze Cliniche, Internistiche, Anestesiologiche e Cardi ( Site 1808)
Rome, Lazio, 00161
Policlinico Gemellli - UOC di cardiologia ( Site 1821)
Rome, Lazio, 168
Ospedale Mauriziano ( Site 1812)
Torino, 10128
Azienda Ospedaliero-Universitaria Città della Salute e della Scienza di Torino ( Site 1801)
Turin, Piedmont, 10126
Peru17 sites
Hogar Clínica San Juan de Dios ( Site 1115)
Arequipa, Ariqipa, 05154
Hospital Alberto Sabogal Sologuren ( Site 1109)
Bellavista, Qallaw, 07011
Policlínico Especializado en Neurología ( Site 1112)
La Perla-Callao, Lima, 07011
Unidad de Investigacon de la Clinica Internacional ( Site 1116)
Lima, 15001
Clínica Internacional - Sede San Borja ( Site 1111)
Lima, 15036
Clínica Vesalio-Cardiology ( Site 1101)
Lima, 15036
Clínica Javier Prado ( Site 1100)
Lima, 15046
Hospital Militar Geriátrico ( Site 1114)
Lima, 15064
CLINICA DELGADO ( Site 1117)
Lima, 15074
Clínica El Golf-Cardiologia ( Site 1103)
Lima, 15076
Clínica Providencia ( Site 1102)
Lima, 15088
Hospital Cayetano Heredia-Servicio de cardiologia ( Site 1113)
Lima, Lima 31
ASOCIACION CIVIL POR LA SALUD ( Site 1107)
Miraflores, Muni Metro de Lima, 15048
Centro de Investigación Clínica Belén ( Site 1108)
Piura, 20000
Instituto Médico Soy Diabetico ( Site 1106)
Piura, 20009
Centro de investigacion Clínica Trujillo-Medical specialties ( Site 1104)
Trujillo, La Libertad, 13001
Clínica San Antonio ( Site 1118)
Trujillo, La Libertad, 13008
Turkey (Türkiye)17 sites
Adana Sehir Egitim ve Arastirma Hastanesi ( Site 2511)
Adana, 01370
Hacettepe Universite Hastaneleri ( Site 2500)
Altindağ, Ankara, 06230
SBÜ GÜLHANE EĞİTİM VE ARAŞTIRMA HASTANESİ ( Site 2524)
Ankara, 06010
Ankara Bilkent Şehir Hastanesi-cardiology ( Site 2501)
Ankara, 06800
Antalya Egitim ve Arastırma Hastanesi-Cardiology ( Site 2518)
Antalya, 07100
Ege Universitesi Hastanesi-Cardilogy Department ( Site 2502)
Bornova, İzmir, 35100
Çanakkale Onsekiz Mart Üniversitesi ( Site 2509)
Çanakkale, 17000
I.E.U. Medical Point Hastanesi ( Site 2521)
Cordaleo, İzmir, 35575
Trakya University ( Site 2523)
Edirne, 22030
Eskisehir Osmangazi University-Cardiology ( Site 2510)
Eskişehir, 26480
Istanbul University Cerrahpasa Medical School Internal Diseases Institute ( Site 2528)
Istanbul, 34098
Marmara Universitesi Pendik Egitim Arastirma Hastanesi ( Site 2520)
Istanbul, 34899
Kocaeli Üniversitesi-Cardiology ( Site 2516)
Kocaeli, 41380
NECMETTIN ERBAKAN MERAM MEDICAL FAC.-cardiology ( Site 2513)
Konya, 42080
İnönü Üniversitesi Turgut Özal Tıp Merkezi ( Site 2525)
Malatya, 44280
Erciyes Universitesi Tıp Fakultesi Hastaneleri-endocrine ( Site 2522)
Melikgazi, Kayseri, 38280
Ondokuz Mayis Universitesi Saglik Uygulama ve Arastirma Merkezi ( Site 2527)
Samsun, 55200
New Zealand16 sites
Waitemata District Health Board ( Site 2915)
Auckland, 0622
New Zealand Clinical Research (Auckland) ( Site 2900)
Auckland, 0624
Waitemata Clinical Research Ltd ( Site 2916)
Auckland, 0626
Auckland City Hospital ( Site 2911)
Auckland, 1023
New Zealand Clinical Research (Christchurch) ( Site 2901)
Christchurch, Canterbury, 8011
Pacific Clinical Research Network - Forte ( Site 2903)
Christchurch, Canterbury, 8013
Momentum Clinical Research Dunedin ( Site 2910)
Dunedin, Otago, 9016
Lakeland Clinical Trials Wellington ( Site 2904)
Ebdentown, Wellington Region, 5018
Momentum Clinical Research Hawke's Bay ( Site 2913)
Hastings, Hawkes Bay, 4122
Momentum Clinical Research Lower Hutt ( Site 2914)
Lower Hutt, Wellington Region, 5010
Lakeland Clinical Trials Waikato ( Site 2906)
Nawton, Waikato Region, 3200
Pacific Clinical Research Network - Tasman ( Site 2905)
Nelson, 7011
Momentum Clinical Research - Palmerston North ( Site 2909)
Palmerston North, Manawatu-Wanganui, 4414
Pacific Clinical Research Network - Rotorua ( Site 2902)
Rotorua, Bay of Plenty, 3010
Momentum Clinical Research - Tauranga ( Site 2907)
Tauranga, Bay of Plenty, 3110
Momentum Clinical Research Kapiti ( Site 2912)
Wellington, 5036
Chile15 sites
Biocenter ( Site 0819)
Concepción, Biobio, 4070196
Espacio Eme ( Site 0806)
Ñuñoa, Region M. de Santiago, 7770086
Servicios Medicos Godoy ( Site 0810)
Providencia, Region M. de Santiago, 7500710
Centro Respiratorio Integral - CENRESIN. ( Site 0820)
Quillota, Valparaiso, 5501775
Enroll SpA ( Site 0803)
Santiago, Region M. de Santiago, 7500587
FALP-UIDO ( Site 0815)
Santiago, Region M. de Santiago, 7500921
CECIM ( Site 0811)
Santiago, Region M. de Santiago, 8320000
Centro de Investigacion Clinicadela Universidad Catolica ( Site 0812)
Santiago, Region M. de Santiago, 8330034
Universidad de Chile - Hospital Clínico Universidad de Chile ( Site 0800)
Santiago, Region M. de Santiago, 8380420
Clínica Ensenada ( Site 0801)
Santiago, Region M. de Santiago, 8380465
Centro de Investigación del Maule ( Site 0816)
Talca, Maule Region, 3460000
Centro de Investigación Clinica Del Sur ( Site 0821)
Temuco, Araucania, 4781156
Centro De Estudios Cardiologicos Y De Medicina Interna ( Site 0805)
Temuco, Araucania, 4813299
Clinical Research Chile SpA ( Site 0804)
Valdivia, Los Ríos Region, 5110683
ONCOCENTRO APYS ( Site 0808)
Viña del Mar, Valparaiso, 2520598
France15 sites
CHRU Troussau-CARDIOLOGY ( Site 1402)
Chambray-lès-Tours, Centre-Val de Loire, 37170
Centre Hospitalier Universitaire Dijon Bourgogne - Hôpital François Mitterrand ( Site 1409)
Dijon, Cote-d Or, 21079
Centre Hospitalier Universitaire de Grenoble-Cardiology ( Site 1421)
Grenoble, Auvergne-Rhône-Alpes, 38700
Centre Hospitalier Louis Pasteur ( Site 1405)
Le Coudray, Eure-et-Loir, 28630
Centre Hospitalier Universitaire de Limoges - Hôpital Dupuytren ( Site 1413)
Limoges, Haute-Vienne, 87042
Clinique du Pont de Chaume ( Site 1407)
Montauban, Tarn-et-Garonne, 82017
Centre Hospitalier Universitaire de Nîmes - Hôpital Universitaire Carémeau ( Site 1401)
Nîmes, Gard, 30029
CENTRE HOSPITALIER REGIONAL D'ORLEANS-Service de Cardiologie ( Site 1416)
Orléans, Centre-Val de Loire, 45067
Pitie Salpetriere University Hospital ( Site 1414)
Paris, Orne, 75013
Centre Hospitalier de Pau ( Site 1408)
Pau, Pyrenees-Atlantiques, 64046
Centre Hospitalier Universitaire de Poitiers ( Site 1417)
Poitiers, Vienne, 86021
Centre Hospitalier Universitaire de Reims - Hôpital Robert Debré ( Site 1418)
Reims, Marne, 51092
Centre Hospitalier Universitaire de Rennes - Hôpital Pontchaillou ( Site 1404)
Rennes, Ille-et-Vilaine, 35000
Centre Hospitalier Universitaire de Saint Étienne - Hôpital Nord ( Site 1400)
Saint Priest En Jarez, Pays de la Loire Region, 42270
Polyclinique Vauban ( Site 1406)
Valenciennes, Nord, 59300
United Kingdom12 sites
West Walk Surgery ( Site 2602)
Bristol, Bristol, City of, BS37 4AX
Velocity Clinical Research Romford ( Site 2615)
Bristol, Bristol, City of, BS8 2RA
Golden Jubilee National Hospital ( Site 2613)
Clydebank, Glasgow City, G81 4DY
Lakeside Surgery ( Site 2601)
Corby, Northamptonshire, NN17 2UR
Royal Devon & Exeter Hospital-Patient Recruitment Centre: Exeter ( Site 2605)
Exeter, Devon, EX2 5DW
Velocity Clinical Research, Leicester ( Site 2614)
Leicester, LE1 6NB
Barts Health NHS Trust-William Harvey Clinical Research Centre ( Site 2603)
London, England, EC1M 6BQ
Manchester Royal Infirmary ( Site 2612)
Manchester, M13 9WL
NIHR Commercial Recruitment Delivery Centre: Newcastle ( Site 2606)
Newcastle upon Tyne, England, NE1 4LP
Velocity Clinical Research Romford ( Site 2618)
Romford, London, City of, RM1 3PJ
Northern General Hospital ( Site 2611)
Sheffield, S5 7AU
Walsall Manor Hospital ( Site 2600)
Walsall, Devon, WS2 9PS
Denmark11 sites
Aarhus Universitetshospital, Skejby ( Site 1201)
Aarhus, Central Jutland, 8200
Herlev and Gentofte Hospital-Department of Cardiology ( Site 1210)
Copenhagen, Capital Region, 2730
Sydvestjysk Sygehus Esbjerg ( Site 1206)
Esbjerg, Region Syddanmark, 6700
Sanos Clinic - Nordjylland ( Site 1203)
Gandrup, North Denmark, 9362
Sanos Clinic-Sanos Clinic ( Site 1204)
Herlev, Capital Region, 2730
Regionshospitalet Gødstrup ( Site 1207)
Herning, Central Jutland, 7400
Sygehus Vendsyssel Hjoerring ( Site 1209)
Hjørring, North Denmark, 9800
Roskilde Sygehus ( Site 1212)
Roskilde, Region Sjælland, 4000
Slagelse Sygehus-Ambulatorium for Hjertesygdomme ( Site 1205)
Slagelse, Region Sjælland, 4200
Svendborg Hospital Odense Universitets hospital-Kardiologisk Forskningsenhed ( Site 1200)
Svendborg, Region Syddanmark, 5700
Sanos Clinic - Syddanmark ( Site 1202)
Vejle, Region Syddanmark, 7100
Canada10 sites
Cambridge Cardiac Care Centre ( Site 0508)
Cambridge, Ontario, N1R 6V6
Ecogene-21 ( Site 0510)
Chicoutimi, Quebec, G7H 7K9
OCT Research ULC ( Site 0512)
Kelowna, British Columbia, V1Y 1Z9
Institut de Cardiologie de Montreal ( Site 0506)
Montreal, Quebec, H1T 1C8
North York Diagnostic and Cardiac Centre ( Site 0514)
North York, Ontario, M6B 3H7
Oakville Cardiovascular Research LP ( Site 0507)
Oakville, Ontario, L6K 3W7
IUCPQ ( Site 0515)
Québec, Quebec, G1V 4G5
Centre intégré de santé et de services sociaux de Lanaudière - Hopital Pierre-Le Gardeur. ( Site 0509)
Terrebonne, Quebec, J6V 2H2
Corcare ( Site 0511)
Toronto, Ontario, M1B 5N1
Diex Recherche Trois-Rivieres ( Site 0505)
Trois-Rivières, Quebec, G9A 4P3
South Korea10 sites
Dong-A University Hospital ( Site 3013)
Busan, Pusan-Kwangyokshi, 49201
Keimyung University Dongsan Hospital CRC room 1 ( Site 3003)
Daegu, Taegu-Kwangyokshi, 42601
Seoul National University Bundang Hospital ( Site 3005)
Seongnam, Kyonggi-do, 13620
Seoul National University Hospital ( Site 3001)
Seoul, 03080
Kangbuk Samsung Hospital ( Site 3009)
Seoul, 03181
Severance Hospital, Yonsei University Health System ( Site 3002)
Seoul, 03722
Asan Medical Center ( Site 3004)
Seoul, 05505
Samsung Medical Center-cardiology ( Site 3000)
Seoul, 06351
The Catholic Univ. of Korea Seoul St. Mary's Hospital ( Site 3007)
Seoul, 06591
Ajou University Hospital ( Site 3006)
Suwon, Kyonggi-do, 16499
Taiwan10 sites
Changhua Christian Hospital ( Site 3101)
Changhua, 50006
Kaohsiung Medical University Hospital ( Site 3109)
Kaohsiung City, 807
Chang Gung Memorial Hospital at Kaohsiung ( Site 3102)
Kaohsiung City, 83301
Mackay Memorial Hospital -Tamsui Branch ( Site 3108)
New Taipei City, New Taipei, 251
China Medical University Hospital ( Site 3103)
Taichung, 404332
Chi Mei Medical Center-Cardiology ( Site 3104)
Tainan, Tainan, 71004
National Taiwan University Hospital ( Site 3100)
Taipei, 10002
Taipei Medical University Hospital-Cardiology ( Site 3107)
Taipei, 110
Taipei Veterans General Hospital ( Site 3106)
Taipei, 112
Tri-Service General Hospital ( Site 3110)
Taipei, 114202
Norway9 sites
Ålesund sjukehus ( Site 2029)
Ålesund, Møre og Romsdal, 6017
Haukeland Universitetssjukehus ( Site 2023)
Bergen, Hordaland, 5021
Nordlandssykehuset ( Site 2021)
Bodø, Nordland, 8005
Sykehuset Innlandet HF Lillehammer-Medisinsk avdeling ( Site 2030)
Lillehammer, Oppland, 2629
Akershus Universitetssykehus-Hjertemedisinsk Avdeling ( Site 2028)
Lorenskog, Akershus, 1478
Oslo Universitetssykehus Aker-Lipidklinikken ( Site 2020)
Oslo, 0316
Colosseumsklinikken AS ( Site 2024)
Oslo, 0369
Oslo Universitetssykehus Rikshospitalet-Kardiologisk avdeling ( Site 2025)
Oslo, 0372
Oslo Universitetssykehus Ullevål ( Site 2031)
Oslo, 0450
Australia7 sites
Paratus Clinical Research Western Sydney ( Site 2805)
Blacktown, New South Wales, 2148
The Prince Charles Hospital ( Site 2810)
Brisbane, Queensland, 4032
Paratus Clinical Research Canberra ( Site 2804)
Bruce, Australian Capital Territory, 2617
Royal Prince Alfred Hospital ( Site 2808)
Camperdown, New South Wales, 2050
Victorian Heart Hospital-Monash Cardiovascular Research Centre (MCRC) ( Site 2803)
Clayton, Victoria, 3168
Baker IDI Heart & Diabetes Institute ( Site 2809)
Hoppers Crossing, Victoria, 3029
Paratus Clinical Research Central Coast ( Site 2806)
Kanwal, New South Wales, 2259
Hong Kong5 sites
Queen Mary Hospital-Medicine - Cardiology ( Site 3303)
Hksar
Queen Mary Hospital-Medical ( Site 3300)
Pok Fu Lam
Prince of Wales Hospital ( Site 3301)
Shatin
Prince of Wales Hospital ( Site 3304)
Shatin
Our Lady of Maryknoll Hospital-Department of Medicine and Geriatrics ( Site 3305)
Wong Tai Sin, 999077
Puerto Rico4 sites
Clinical Research Investigator Group ( Site 3701)
Bayamón, 00960
Investigadores del Este LLC ( Site 3700)
Humacao, 00791
Ponce Medical School Foundation Inc. ( Site 3702)
Ponce, 00716
Latin Clinical Trial Center ( Site 3704)
San Juan, 00909
About this study
Official title: Phase 3 Randomized, Placebo-Controlled Clinical Study to Evaluate the Efficacy and Safety of MK-0616 in Reducing Major Adverse Cardiovascular Events in Participants at High Cardiovascular Risk
This is a phase 3, randomized, placebo-controlled study of the efficacy and safety of enlicitide decanoate, an oral proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitor, in participants with high cardiovascular risk. The primary objective is to evaluate the efficacy of enlicitide decanoate compared with placebo in increasing the time to the first occurrence of major adverse cardiovascular events (MACE) including coronary heart disease (CHD) death, ischemic stroke, myocardial infarction (MI), acute limb ischemia or major amputation, or urgent arterial revascularization.
- Conditions
- Arteriosclerosis, Hypercholesterolaemia
- Being tested
- Enlicitide Decanoate, Placebo
- Medical subject headings
- Arteriosclerosis, Hypercholesterolemia
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
Enlicitide DecanoateDrug
Also called MK-0616
Enlicitide Decanoate 20 mg tablet taken by mouth.
PlaceboDrug
Placebo tablet matched to enlicitide decanoate taken by mouth.
| Study group | Role | What they receive |
|---|---|---|
| Blinded Portion: Enlicitide Decanoate | Experimental | Participants receive enlicitide decanoate 20 mg once daily. Receives: Drug: Enlicitide Decanoate |
| Blinded Portion: Placebo | Placebo comparator | Participants receive placebo once daily. Receives: Drug: Placebo |
| Open-Label Extension: Enlicitide Decanoate | Experimental | Participants who complete the blinded portion may enroll in this open-label extension arm. Participants in the extension arm receive enlicitide decanoate once daily up to 2 years. Receives: Drug: Enlicitide Decanoate |
What is being measured
The primary outcome is the main question the study is designed to answer.
Blinded Period: Time to First Occurrence of Coronary Heart Disease (CHD) Death-Based Major Adverse Cardiovascular Events (MACE)-Plus
Time to the first occurrence of CHD death-based MACE-plus, which is defined as any of the following: coronary heart disease death, myocardial infarction (MI), ischemic stroke (fatal and nonfatal), acute limb ischemia or major amputation, or urgent arterial revascularization (coronary, cerebrovascular, or peripheral).
Measured: From date of randomization until the date of first occurrence of CHD death-based MACE-plus, assessed up to approximately 6 years
Secondary outcomes (17)
Blinded Period: Time to First Occurrence of 3-point MACE
Time to the first occurrence of 3-point MACE (defined as cardiovascular death, MI, or ischemic stroke).
Measured: From date of randomization until the date of first occurrence of 3-point MACE, assessed up to approximately 6 years
Blinded Period: Time to First Occurrence of Cardiovascular (CV) Death-Based MACE Plus
Time to the first occurrence of CV death-based MACE plus, defined as any of the following: cardiovascular death, MI, ischemic stroke, acute limb ischemia or major amputation, or urgent arterial revascularization (coronary, cerebrovascular, or peripheral).
Measured: From date of randomization until the date of first occurrence of CV death-based MACE plus, assessed up to approximately 6 years
Blinded Period: Time to First Occurrence of CHD Death or MI
Time to the first occurrence of CHD death or MI.
Measured: From date of randomization until the date of first occurrence of CHD death or MI, assessed up to approximately 6 years
Blinded Period: Time to CV Death
Time to cardiovascular death.
Measured: From date of randomization until the date of CV death, assessed up to approximately 6 years
Blinded Period: Time to All-Cause Death
Time to all-cause death.
Measured: From date of randomization until the date of death, assessed up to approximately 6 years
Blinded Period: Time to CHD Death
Time to CHD death.
Measured: From date of randomization until the date of CHD death, assessed up to approximately 6 years
Blinded Period: Time to First Event of MI
Time to the first occurrence of MI.
Measured: From date of randomization until the date of MI, assessed up to approximately 6 years
Blinded Period: Time to First Event of Ischemic Stroke
Time to the first occurrence of ischemic stroke.
Measured: From date of randomization until the date of first occurrence of ischemic stroke, assessed up to approximately 6 years
Blinded Period: Time to First Event of Acute Limb Ischemia or Major Amputation
Time to the first occurrence of acute limb ischemia or major amputation.
Measured: From date of randomization until the date of first occurrence of acute limb ischemia or major amputation, assessed up to approximately 6 years
Blinded Period: Time to First Event of Urgent Arterial Revascularization
Time to the first occurrence of urgent arterial revascularization (coronary, cerebrovascular, or peripheral).
Measured: From date of randomization until the date of urgent arterial revascularization, assessed up to approximately 6 years
Blinded Period: Percent Change from Baseline in Low-Density Lipoprotein Cholesterol (LDL-C)
The percent change from baseline in LDL-C.
Measured: Baseline and Week 52
Blinded Period: Percent Change from Baseline in Apolipoprotein B
The percent change from baseline in apolipoprotein B.
Measured: Baseline and Week 52
Blinded Period: Percent Change from Baseline in Non-High-Density Lipoprotein Cholesterol (non-HDL-C) cholesterol
The percent change from baseline in Non-HDL-C.
Measured: Baseline and Week 52
Blinded Period: Percent Change from Baseline in Lipoprotein (a)
The percent change from baseline in lipoprotein (a).
Measured: Baseline and Week 52
Blinded Period: Number of Participants with an Adverse Event (AE)
An AE is any untoward medical occurrence in a clinical study participant, temporally associated with the use of study intervention, whether or not considered related to the study intervention. The number of participants with AE(s) in each arm will be reported.
Measured: Up to approximately 6 years
Blinded Period: Number of Participants Discontinuing from Study Therapy Due to AE
An AE is any untoward medical occurrence in a clinical study participant, temporally associated with the use of study intervention, whether or not considered related to the study intervention. The number of participants discontinuing due to AE(s) in each arm will be reported.
Measured: Up to approximately 6 years
Open-Label Extension (OLE): Time to First Occurrence of CHD Death-Based MACE Plus
Time to the first occurrence of CHD death-based MACE-plus, which is defined as any of the following: coronary heart disease death, MI, ischemic stroke (fatal and nonfatal), acute limb ischemia or major amputation, or urgent arterial revascularization (coronary, cerebrovascular, or peripheral).
Measured: From date of randomization until the date of first occurrence of CHD death-based MACE plus, assessed up to approximately 8 years
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted24 Aug 2023
- Study start9 Oct 2023
- Primary completion29 Nov 2029 (estimated)
- Study completion29 Nov 2031 (estimated)
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Other trials for ArteriosclerosisStudies of the same condition, open and under way.
- More trials run by Merck Sharp & Dohme LLCThe sponsor's other registered studies.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Interventional
- Phase
- Phase 3
- Primary purpose
- Treatment
- Allocation
- Randomised
- Intervention model
- Parallel groups
- Model description
- There are two parts of the study. The blinded period is randomized parallel treatment groups. Participants who complete the blinded period are then eligible to enroll in an open label extension (OLE) (single group).
- Masking
- Triple blind
- Who is masked
- Participant, Investigator, Outcomes assessor
- Enrolment
- 14,550 participants (estimated)
Sponsor and investigators
- Lead sponsor
- Merck Sharp & Dohme LLC
- Sponsor type
- Industry (pharma, biotech, devices)
- Responsible party
- Sponsor
- Investigators
- Medical Director, Study director, Merck Sharp & Dohme LLC
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT06008756
- Sponsor's protocol ID
- 0616-015
- Other IDs
- jRCT2071230064, 2022-502781-24-00, U1111-1285-4245
- Status last verified
- Apr 2026
- First submitted
- 17 Aug 2023
- Last updated
- 23 Apr 2026
- Results posted
- No
- Data monitoring committee
- Yes
- FDA-regulated drug
- Yes
- FDA-regulated device
- No
- Individual data sharing
- Yes: https://trialstransparency.msdclinicaltrials.com/pdf/ProcedureAccessClinicalTrialData.pdf
Study at a glance
From the registry record, last updated by the sponsor on 23 Apr 2026. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- Phase 3 Randomized, Placebo-Controlled Clinical Study to Evaluate the Efficacy and Safety of MK-0616 in Reducing Major Adverse Cardiovascular Events in Participants at High Cardiovascular Risk
- ClinicalTrials.gov ID
- NCT06008756
- Acronym / sponsor ID
- 0616-015
- Conditions
- Arteriosclerosis, Hypercholesterolaemia
- Phase
- Phase 3
- Study type
- Interventional
- Recruitment status
- Active, not recruiting
- Enrolment
- 14,550 participants (estimated)
- Lead sponsor
- Merck Sharp & Dohme LLCIndustry (pharma, biotech, devices)
- Study start
- 9 Oct 2023 (actual)
- Primary completion
- 29 Nov 2029 (estimated)
- Study completion
- 29 Nov 2031 (estimated)
- First posted
- 24 Aug 2023 (actual)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
This is a phase 3, randomized, placebo-controlled study of the efficacy and safety of enlicitide decanoate, an oral proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitor, in participants with high cardiovascular risk. The primary objective is to evaluate the efficacy of enlicitide decanoate compared with placebo in increasing the time to the first occurrence of major adverse cardiovascular events (MACE) including coronary heart disease (CHD) death, ischemic stroke, myocardial infarction (MI), acute limb ischemia or major amputation, or urgent arterial revascularization.
Study design
- Primary purpose
- Treatment
- Allocation
- Randomised
- Intervention model
- Parallel groups
- Masking
- Triple blind (participant, investigator, outcomes assessor)
- Number of arms
- 3
- Model description
- There are two parts of the study. The blinded period is randomized parallel treatment groups. Participants who complete the blinded period are then eligible to enroll in an open label extension (OLE) (single group).
| Arm | Type | Receives |
|---|---|---|
| Blinded Portion: Enlicitide Decanoate | Experimental | Drug: Enlicitide DecanoateParticipants receive enlicitide decanoate 20 mg once daily. |
| Blinded Portion: Placebo | Placebo comparator | Drug: PlaceboParticipants receive placebo once daily. |
| Open-Label Extension: Enlicitide Decanoate | Experimental | Drug: Enlicitide DecanoateParticipants who complete the blinded portion may enroll in this open-label extension arm. Participants in the extension arm receive enlicitide decanoate once daily up to 2 years. |
Who may qualify
- Ages
- 18 years and older
- Sex
- All
- Healthy volunteers
- Not accepted
- Age groups
- Adult, Older adult
Key inclusion criteria (8 listed)
- Meets one of the following:
- Has fasted lipid values (evaluated by the Central Laboratory) at Visit 1 (Screening) as follows:
- Is treated with moderate- or high-intensity statin (± nonstatin lipid-lowering therapy [LLT]) at Visit 1
- Is on a stable dose of all background LLTs (including statin and nonstatin agents) for at least 30 days before Visit 1 (Screening) with no medication or dose changes planned during the participation in the study
Key exclusion criteria (7 listed)
- Has a history of homozygous familial hypercholesterolemia (FH) based on genetic or clinical criteria, compound heterozygous FH, or double heterozygous FH
- Has New York Heart Association Class IV heart failure, last known Left Ventricular Ejection Fraction ≤25% by any imaging method, or had a Heart Failure hospitalization within 3 months before Visit 1 (Screening)
- Has recurrent ventricular tachycardia within 3 months prior to randomization
- Has a planned arterial revascularization procedure
- Is undergoing or previously underwent an LDL-C apheresis program within 3 months before Visit 1 (Screening) or plans to initiate an LDL-C apheresis program
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Interventions
| Intervention | Type | Arms |
|---|---|---|
| Enlicitide DecanoateAlso: MK-0616Enlicitide Decanoate 20 mg tablet taken by mouth. | Drug | Blinded Portion: Enlicitide Decanoate, Open-Label Extension: Enlicitide Decanoate |
| PlaceboPlacebo tablet matched to enlicitide decanoate taken by mouth. | Drug | Blinded Portion: Placebo |
Primary outcome
Blinded Period: Time to First Occurrence of Coronary Heart Disease (CHD) Death-Based Major Adverse Cardiovascular Events (MACE)-Plus
Time frame: From date of randomization until the date of first occurrence of CHD death-based MACE-plus, assessed up to approximately 6 years
Time to the first occurrence of CHD death-based MACE-plus, which is defined as any of the following: coronary heart disease death, myocardial infarction (MI), ischemic stroke (fatal and nonfatal), acute limb ischemia or major amputation, or urgent arterial revascularization (coronary, cerebrovascular, or peripheral).
17 secondary outcomes
Blinded Period: Time to First Occurrence of 3-point MACE
Time frame: From date of randomization until the date of first occurrence of 3-point MACE, assessed up to approximately 6 years
Blinded Period: Time to First Occurrence of Cardiovascular (CV) Death-Based MACE Plus
Time frame: From date of randomization until the date of first occurrence of CV death-based MACE plus, assessed up to approximately 6 years
Blinded Period: Time to First Occurrence of CHD Death or MI
Time frame: From date of randomization until the date of first occurrence of CHD death or MI, assessed up to approximately 6 years
Blinded Period: Time to CV Death
Time frame: From date of randomization until the date of CV death, assessed up to approximately 6 years
Blinded Period: Time to All-Cause Death
Time frame: From date of randomization until the date of death, assessed up to approximately 6 years
Blinded Period: Time to CHD Death
Time frame: From date of randomization until the date of CHD death, assessed up to approximately 6 years
Blinded Period: Time to First Event of MI
Time frame: From date of randomization until the date of MI, assessed up to approximately 6 years
Blinded Period: Time to First Event of Ischemic Stroke
Time frame: From date of randomization until the date of first occurrence of ischemic stroke, assessed up to approximately 6 years
Blinded Period: Time to First Event of Acute Limb Ischemia or Major Amputation
Time frame: From date of randomization until the date of first occurrence of acute limb ischemia or major amputation, assessed up to approximately 6 years
Blinded Period: Time to First Event of Urgent Arterial Revascularization
Time frame: From date of randomization until the date of urgent arterial revascularization, assessed up to approximately 6 years
Blinded Period: Percent Change from Baseline in Low-Density Lipoprotein Cholesterol (LDL-C)
Time frame: Baseline and Week 52
Blinded Period: Percent Change from Baseline in Apolipoprotein B
Time frame: Baseline and Week 52
Blinded Period: Percent Change from Baseline in Non-High-Density Lipoprotein Cholesterol (non-HDL-C) cholesterol
Time frame: Baseline and Week 52
Blinded Period: Percent Change from Baseline in Lipoprotein (a)
Time frame: Baseline and Week 52
Blinded Period: Number of Participants with an Adverse Event (AE)
Time frame: Up to approximately 6 years
Blinded Period: Number of Participants Discontinuing from Study Therapy Due to AE
Time frame: Up to approximately 6 years
Open-Label Extension (OLE): Time to First Occurrence of CHD Death-Based MACE Plus
Time frame: From date of randomization until the date of first occurrence of CHD death-based MACE plus, assessed up to approximately 8 years
Results and safety
This study is still under way. Results are not available in the source record yet.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 23 Apr 2026.
- Merck Clinical Trials InformationLink provided by the sponsor.
- Individual participant dataSharing planned: Yes. https://trialstransparency.msdclinicaltrials.com/pdf/ProcedureAccessClinicalTrialData.pdf
Related trials for Arteriosclerosis
Active, not recruitingPhase 4
Effects of Sequential Therapy With Mexidol® (Intravenous) and Mexidol® FORTE 250 (Oral) on Functional Brain Activity Assessed by Functional Magnetic Resonance Imaging and Biochemical Parameters in Patients With Chronic Cerebral Ischemia: A Comparison of Patients With and Without Metabolic Disorders
Metabolic Abnormalities, Obesity & Overweight
Not yet recruitingPhase 4
Roxadustat and Myocardial Injury After Off-Pump Coronary Artery Bypass Surgery
Coronary Artery Disease, Coronary Artery Bypass Grafting
RecruitingObservational study
Preoperative Gastric Ultrasound and Left Ventricular Function in Coronary Artery Bypass Surgery
Coronary Artery Disease, Left Ventricular Systolic Dysfunction
Active, not recruiting
The OCTOBER Trial - European Trial on Optical Coherence Tomography Optimized Bifurcation Event Reduction (OCTOBER)
Ischaemic Heart Disease, Ischemic Heart Disease
Not yet recruitingObservational study
Preoperative Gastric Ultrasound and Anaesthetic Management in Patients Undergoing Coronary Artery Bypass Grafting
Preoperative Fasting, Pulmonary Aspiration During Anesthetic Induction
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part. This study is not recruiting at the moment.
Medical Director study director
Merck Sharp & Dohme LLC
669 sites in 29 countries: see every site and its status.
Questions about this trial
What is this clinical trial studying?
A Phase 3 study testing Enlicitide Decanoate in people with Arteriosclerosis and Hypercholesterolaemia, run by Merck Sharp & Dohme LLC at 669 sites in 29 countries.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 8 inclusion and 7 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: under way, not looking for participants, as of the sponsor's last update on 23 Apr 2026. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 669 sites in United States, China, Japan, Netherlands, Poland and 24 more countries. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. Some participants in this study may receive a placebo. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
What does this phase mean?
Phase 3 studies compare the treatment with the current standard treatment or a placebo in a large group, to confirm how well it works and watch for side effects.
Not every study follows the same path, and some studies (observational studies, device studies) have no phase.
Are results available for this study?
This study is still under way. Results are not available in the source record yet.
How can a doctor refer a patient or contact the research team?
The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
Blinded Period: Time to First Occurrence of Coronary Heart Disease (CHD) Death-Based Major Adverse Cardiovascular Events (MACE)-Plus (time frame: From date of randomization until the date of first occurrence of CHD death-based MACE-plus, assessed up to approximately 6 years). It is what the study was designed to measure, not a finding.
Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 23 Apr 2026.